Abstract Biotinidase deficiency is an autosomal recessive metabolic disorder included in many newborn screening programmes.
such as neurological impairment, hypotonia, alopecia, hearing loss, eye problems, skin rash, lactic acidosis and ketosis. Once developmental delay, vision and hearing problems have occurred, they are usually irreversible. Early treatment with pharmacological doses of biotin prevents symptom. Therefore, many countries include BD in their newborn screening programme. Patients with profound BD (residual activity<10%), as well as those with partial BD (residual activity 10-30%), have been identified. Long-term follow-up studies indicate that the majority of patients with partial BD will stay asymptomatic without treatment (Möslinger et al. 2001) , but there are also reports of patients exhibiting symptoms during stress, such as infections (McVoy et al. 1990 ).
The human biotinidase gene (OMIM 609019) was mapped and characterised in 1994 (Cole et al. 1994a; b) . The gene has four exons with a total length of 1,629 base pairs (Knight et al. 1998) . To date, 110 mutations have been described but only a few are common (www.hmgd.cf.ac.uk). The mutation spectrum differs between clinically diagnosed patients and patients ascertained by newborn screening. The two most frequently sited mutations causing profound BD in symptomatic children are p.G98:d7i3 and p.R538C . A missense mutation p.Q456H and a double mutation p.[A171T;D444H] are the most frequently sited mutations in children ascertained by newborn screening (Norrgard et al. 1997 ). Partial BD is almost universally caused by p.D444H, a mutation resulting in an enzyme with approximately 50% residual activity (Swango et al. 1998) . Patients carrying this mutation in combination with a mutation on the second allele associated with profound BD can be detected through newborn screening.
Approximately 100,000 newborns, adoptive children and immigrants younger than 18 years are screened yearly at the national screening laboratory in Sweden. Five disorders are included in the programme: phenylketonuria (since 1965); galactosemia (since 1967); congenital hypothyroidism (since 1980); congenital adrenal hyperplasia (since 1986) and BD (since 2002). One patient has been diagnosed with BD based on clinical symptoms. Reports from other European countries indicate an incidence of 1-2 cases per 100,000 newborns. This prompted us to investigate whether cases are missed by performing a screening trial. The trial was included in the Swedish newborn screening programme in 1988 and stopped when 215,000 children had been screened. The cutoff level was set to detect patients with profound BD. One patient was diagnosed during the study period. The study was discontinued due to the low frequency of patients detected.
In November 2002, screening for BD was reintroduced in the screening programme with the aim of identifying patients with profound BD. Here we report the experience of screening 637,452 newborns and 5,068 adoptive/immigrant children for BD over a period of 6 years.
Methods

Patients
From November 2002 to December 2008, 642,520 children were screened (637,452 newborns and 5,068 adoptive/ immigrant children). Thirteen children with BD were identified during the study period: six with profound and seven with partial BD. Blood for DNA analysis was requested from the children and their parents. The project was approved by the Regional Ethical Committee of Stockholm.
Enzyme assay
Biotinidase activity was determined with a semiquantitative fluorometric method using biotin 6-amidoquinoline as substrate (Wastell et al. 1984) . Dried blood spot filter paper (ø3mm) samples were incubated at 37°C in dark microtiter plates for 5 h in a reaction mixture of 50 μl containing potassium phosphate buffer (0.15 M, pH 6.5), dithioerythritol 1.5 mM and biotinidase substrate (B6-AQ) 0.075 mM. After addition of 250µl ethanol, the plates were incubated at room temperature for an hour. The samples were centrifuged at 3,000 rpm for 5 min. Fluorescence was measured on a Wallac Victor 2 1420 Multilabel Counter at the excitation wavelength of 355 nm and emission wavelength of 535 nm. The cutoff value was first set at 25% of the mean activity of samples obtained the same day but in 2006 was lowered to 20% to reduce the number of false positives. A second blood spot filter paper and a heparinised plasma sample for quantitative determination of biotinidase activity were requested from the recalled infants. Plasma biotinidase activity was assayed with B6-AQ as substrate as described by Wastell et al. (1984) , with an incubation time of 120 min. The Swedish national neonatal screening laboratory performed all analyses.
DNA isolation, polymerase chain reaction (PCR) and direct sequencing Mutation analysis was performed when the quantitative determination of biotinidase activity confirmed the diagnosis of profound or partial BD. DNA was extracted from whole blood using QIAamp® DNA Blood Mini Kit for DNA purification from blood. Primers and polymerase chain reaction (PCR) conditions were as described by Wolf et al. 2005 . Annealing conditions were as follows: exons 2 and 3, 56°C; exons 4a and 4c, 58°C; exons 4b and 4d, 60°C.
Results and discussion
A total of 24 children were recalled during the study period, and 13 cases of BD were confirmed. All but one child was diagnosed during the newborn period (average age 11 days) and started on orally administered biotin supplements 5-10 mg daily soon after diagnosis. As it is not clear whether patients with partial BD need treatment, we chose to treat all patients with biotin supplement. The late-diagnosed child, born in Egypt to consanguineous parents, was diagnosed with profound BD by screening after arrival in Sweden at 1 year of age. Fifteen mutations and three polymorphisms were identified, three of them by studying family members of patients. Nine of the 18 alterations have not been described before (Table 1) . Clinically, five alterations are considered severe mutations, whilst two are mild and two are polymorphisms.
SIFT and PolyPhen analyzing tools
Mutations that were predicted to be disease causing, according to patients' biotinidase activity in plasma, were analysed by two prediction tools: SIFT (sorting intolerant from tolerant; http://sift.jcvi.org/) and PolyPhen (polymorphism phenotyping; http://www.bork.embl-heidelberg.de/ PolyPhen/data). SIFT (Kumar et al. 2009 ) and PolyPhen (Ramensky et al. 2002) predict the effects of an amino acid substitution on protein structure and function. Results were compared to the phenotype of the patient (Table 2) . Both SIFT and PolyPhen have been shown to correctly predict almost 70% of single nucleotide alterations associated with disease that affects protein function (Wang et al. 2009 ).
Profound biotinidase deficiency
Six patients were diagnosed as having profound BD with a biotinidase activity of <10% in plasma (Table 1) . Four of them have consanguineous parents, all of Middle Eastern or African origin. The only symptoms that could possibly be connected to BD observed in the patients were dry skin. The late-diagnosed patient from Egypt was heterozygous for two different mutations, p.L83S and p.P497S, despite consanguineous parents. The novel mutation p.L83S was predicted by both SIFT and PolyPhen to be deleterious, which corresponds well with the patient's phenotype. The patient's father was heterozygous for the novel mutation p.L83S and a new silent mutation, p.L71L (c.211C>T). The patient had not developed symptoms at the time of diagnosis.
Two patients with profound BD were of Iraqi origin. One was homozygous for the novel p.G445R (c.1333G>A) mutation and the other heterozygous for p.R157H and the novel p.G445R mutation. A substitution of the same amino acid, p.G445V (c.1334G>T) has earlier been described in symptomatic patients Norrgard et al. 1999) . All alleles with the p.G445R also carried a novel silent mutation, p.L215L (c.645C>T) in cis. Both SIFT and PolyPhen predict p.G445R to be deleterious, which corresponds well with the patient's biotinidase activity of 0.7 nkat/L plasma (ref value 62-143 nkat/L). Two patients were homozygous for the common p.T532M mutation-one of Syrian origin and the other of Swedish/ Spanish origin. This was the most common mutation among our patients. The patient of Swedish origin was heterozygous for the double mutation p.[A171T;D444H], which is often found in patients detected by newborn screening programmes, and the novel p.I255T (c.764T>C) mutation. The latter mutation is predicted as borderline by SIFT and PolyPhen, but according to the patient's biotinidase activity in plasma, which was immeasurable, we consider p.I255T to be a severe mutation associated with profound BD.
Partial biotinidase deficiency
Mutations were determined in six of the seven patients with partial BD. The mutation p.D444H (c.1330G>C), which is almost universally the cause of partial BD, was found in all but two patients. The p.D444H mutation causes approximately 50% reduction of enzyme activity in the affected allele. This is similar to the Duarte variant in galactose-1-phosphate uridyltransferase deficiency (Elsas et al. 1994) . In this group of patients, two novel mutations were found. A patient of Ethiopian origin was heterozygous for p.P497S (c.1489C>T), a well known null mutation, and the novel p.N202I (c.605A>T) mutation. The patient had a biotinidase activity of 20 nkat/L plasma (reference value 62-143 nkat/L). The mutation is thus considered a less severe mutation. This is in agreement with the predicted severity by SIFT-borderline, and PolyPhen-possibly damaging. The second novel mutation is p.L405P (c.1214T>C). The patient, of Swedish origin, carried the common p.D444H on the other allele. Considering that p.D444H has a rest activity of 50% and the patient's plasma biotinidase activity was 17 nkat/L plasma (reference value 62-143 nkat/L), p.L405P ought to be a severe mutation, probably associated with profound BD. Both SIFT and PolyPhen predict it to be a severe mutation.
Family screening
The complete biotinidase gene was sequenced in two parents who had reduced biotinidase activity in plasma. The father of the patient, who was heterozygous for p.D444H and p.T532M, was heterozygous for the common p.T532M mutation and the novel p.N402S mutation. This mutation is considered borderline and potentially damaging by SIFT and PolyPhen, respectively. His biotinidase activity was 39 nkat/L plasma (reference value 62-143 nkat/L), which makes it likely that p.N402S affects the protein to some extent. The mother of the patient from Ethiopia was heterozygous for two novel mutations: for the one found in the child, p.N202I, which we considered a less severe mutation, but also for p.R148H (c.443G>A). The mother's plasma biotinidase activity was 36 nkat/L plasma (reference value 62-143 nkat/L). According to this value, we think that p.R148H affects the protein more than p.N202I, which gave a SIFT (sorting tolerant from intolerant) predicts a particular nonsynonymous single nucleotide polymorphism (nsSNP) with scores <0.05 as intolerant, 0.051-0.10 as potentially tolerant, 0.101-0.20 as borderline, and 0.201-1.00 as tolerant b PolyPhen (polymorphism phenotyping) predicts a particular nsSNP with scores≥2.00 as probably damaging, 1.50-1.99 as possibly damaging, 1.25-1.49 as potentially damaging, 1.00-1.24 as borderline and 0.00-0.99 as benign a phenotype of partial BD together with p.P497S in the child. SIFT predicts p.R148H to be potentially tolerant, whereas PolyPhen predicts it to be probably damaging. Both parents were asymptomatic. An 8-year-old sibling to one of the Iraqi patients was diagnosed with BD when biotinidase activity was measured in all family members. This patient showed no clinical symptoms and had no abnormal biochemical findings, such as ketolactic acidosis or organic aciduria at the time of diagnosis. The patient is homozygous for p.R157C and has a biotinidase activity of 11 nkat/L plasma (reference value 62-143 nkat/L). The polymorphism c.1284C>T (p.Y428Y) was detected in cis with p.P497S, together with novel mutations on the second allele in the patients from Egypt and Ethiopia, respectively. A third patient, who is Iraqi, was homozygous for p.R157C and p.Y428Y. We found three earlier reports of patients of African origin in the literature. Two reports are by Wolf et al. (2002 and describing a patient from Morocco and one from Nigeria. The third report was published recently and describes four patients of Somali origin (Sarafoglou et al. 2009 ). The patient from Nigeria, as with our two patients, carries the gene alternation p.Y428Y and p.P497S in cis on one allele but together with a double mutation p.[H53Q;Q54X] on the second allele. The patient from Morocco was homozygous for a frameshift mutation. It is not stated whether this patient carries the polymorphism p.Y428Y. Two Somalian patients were heterozygous for p.P497S, p.P142T and p.Y428Y. It is, however, not clarified whether p.Y428Y was in cis with p.P497S in these cases. Further studies are necessary to determine whether p.P497S is a prevalent mutation in patients of African origin and whether the polymorphism p.Y428Y occurs more frequently in the African population than the reported 1.4% in the North American population (http://www.ncbi.nlm.nih.gov/SNP).
Only four mutations were detected in more than one patient. The two most common mutations were p.D444H (five patients) associated with partial BD (Swango et al. 1998 ) and p.T532M (three patients) associated with mild and/or late-onset symptoms (Pomponio et al. 2000) . The only other two mutations detected in more than one patient were p.G445R and p.P497S. No patients were found carrying the two most frequently sited mutations that occur in symptomatic patients with BD in the United States: p.G98:d7i3 and p.R538C (Norrgard et al. 1999 ).
Incidence of biotinidase deficiency
Screening 637,452 newborns for BD shows a total incidence of 1:53,000 for the disease, 1:127,000 for profound BD (n=5) and 1:91,000 for partial BD (n=7), which is similar to that found in other Western countries. If children of Swedish or mixed Swedish origin only are included (n=2), the incidence of profound BD is approximately 1:300,000. Approximately 13,000 children with both parents of Iraqi origin were born in Sweden during the 6-year study period. The incidence of BD in this subgroup could thus be estimated to 1:4,500. We found no published data on how common the disease is in Iraq. A publication from nearby Turkey gives the incidence to be 1:11,600 (Baykal et al. 1998 ). Thus, the disease seems to be more common in Middle Eastern than in Western countries (Wolf 1991) , which may be due to the high incidence of consanguinity in that part of the world.
Conclusions
Characterization of this Swedish biotinidase population demonstrated a heterogeneity of disease causing mutations. Fifteen mutations and three polymorphisms were detected. Seven mutations were novel, five of which were identified in patients and two found in parents. According to biotinidase activity in plasma, five mutations-p.L83S, p.R148H, p.I255T, p.L405P and p.G445R-are considered severe and associated with profound BD. All novel mutations were analysed with the prediction tools SIFT and PolyPhen. Four (p.L83S, p.R148H, p.L405P and p.G445R) of the five mutations we consider severe were predicted as probably damaging by PolyPhen. The fifth mutation, p.I255T, was predicted as borderline. SIFT predicted three (p.L83S, p.L405P and p.G445R) of the five as intolerant.
An older healthy sibling of one of our patients was diagnosed with partial BD. Two parents also had biotinidase activity lower than the heterozygote interval in plasma but not low enough to be diagnosed as partial BD. They both carried novel mutations on one allele and a common mutation on the other. We agree with Baykal et al. (2005) that one should perform family investigation for BD when an index patient is diagnosed.
BD has been considered a rare disease in Sweden, with only one known case diagnosed on the basis of clinical symptoms. In 637,452 screened newborns, one patient of Swedish origin was diagnosed with profound BD. A second child born, to a Swedish mother and a Spanish father, was also diagnosed with profound BD. In the trial screening in 1988, one patient was diagnosed with profound BD in 215,000 screened newborns. Both studies confirm that the incidence of profound BD in the native Swedish population is thus very low. Three patients with consanguineous parents of Middle Eastern or African origin were also diagnosed with profound BD as newborns. Due to the high rate of immigrants since 1990 from non-Nordic countries, the incidence of profound BD in the Swedish population is 1/127,000, similar to that found in many other Western countries (Wolf 1991) . We therefore decided to include BD in the Swedish neonatal screening programme.
